Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides KJ Rayner, CC Esau, FN Hussain, AL McDaniel, SM Marshall, ... Nature 478 (7369), 404-407, 2011 | 825 | 2011 |
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling A Dávalos, L Goedeke, P Smibert, CM Ramírez, NP Warrier, U Andreo, ... Proceedings of the National Academy of Sciences 108 (22), 9232-9237, 2011 | 736 | 2011 |
MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1 CM Ramirez, A Dávalos, L Goedeke, AG Salerno, N Warrier, ... Arteriosclerosis, thrombosis, and vascular biology 31 (11), 2707-2714, 2011 | 298 | 2011 |
MicroRNAs in metabolic disease C Fernández-Hernando, CM Ramírez, L Goedeke, Y Suárez Arteriosclerosis, thrombosis, and vascular biology 33 (2), 178-185, 2013 | 290 | 2013 |
Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis A Wagschal, SH Najafi-Shoushtari, L Wang, L Goedeke, S Sinha, ... Nature medicine 21 (11), 1290-1297, 2015 | 272 | 2015 |
MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels L Goedeke, N Rotllan, A Canfrán-Duque, JF Aranda, CM Ramírez, ... Nature medicine 21 (11), 1280-1289, 2015 | 263 | 2015 |
Regulation of cholesterol homeostasis L Goedeke, C Fernández-Hernando Cellular and Molecular Life Sciences 69, 915-930, 2012 | 253 | 2012 |
Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144 CM Ramírez, N Rotllan, AV Vlassov, A Dávalos, M Li, L Goedeke, ... Circulation research 112 (12), 1592-1601, 2013 | 244 | 2013 |
Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes P Willeit, P Skroblin, AR Moschen, X Yin, D Kaudewitz, A Zampetaki, ... Diabetes 66 (2), 347-357, 2017 | 239 | 2017 |
Acetyl‐C o A Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents L Goedeke, J Bates, DF Vatner, RJ Perry, T Wang, R Ramirez, L Li, ... Hepatology 68 (6), 2197-2211, 2018 | 215 | 2018 |
MicroRNA 33 regulates glucose metabolism CM Ramírez, L Goedeke, N Rotllan, JH Yoon, D Cirera-Salinas, ... Molecular and cellular biology 33 (15), 2891-2902, 2013 | 172 | 2013 |
A regulatory role for microRNA 33* in controlling lipid metabolism gene expression L Goedeke, FM Vales-Lara, M Fenstermaker, D Cirera-Salinas, ... Molecular and cellular biology 33 (11), 2339-2352, 2013 | 160 | 2013 |
Rabin-Court RJ Perry, D Zhang, MT Guerra, AL Brill, L Goedeke, AR Nasiri Wang Y, Peng L, Dufour S, Zhang Y, Zhang XM, Butrico GM, Toussaint K, Nozaki …, 2020 | 143 | 2020 |
Long‐term therapeutic silencing of miR‐33 increases circulating triglyceride levels and hepatic lipid accumulation in mice L Goedeke, A Salerno, CM Ramírez, L Guo, RM Allen, X Yin, SR Langley, ... EMBO molecular medicine 6 (9), 1133-1141, 2014 | 142 | 2014 |
Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis RJ Perry, D Zhang, MT Guerra, AL Brill, L Goedeke, AR Nasiri, ... Nature 579 (7798), 279-283, 2020 | 126 | 2020 |
microRNAs in lipoprotein metabolism and cardiometabolic disorders N Rotllan, N Price, P Pati, L Goedeke, C Fernández-Hernando Atherosclerosis 246, 352-360, 2016 | 119 | 2016 |
Absence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis B Aryal, AK Singh, X Zhang, L Varela, N Rotllan, L Goedeke, B Chaube, ... JCI insight 3 (6), 2018 | 107 | 2018 |
Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice X Li, D Zhang, DF Vatner, L Goedeke, SM Hirabara, Y Zhang, RJ Perry, ... Proceedings of the National Academy of Sciences 117 (51), 32584-32593, 2020 | 104 | 2020 |
Genetic ablation of miR-33 increases food intake, enhances adipose tissue expansion, and promotes obesity and insulin resistance NL Price, AK Singh, N Rotllan, L Goedeke, A Wing, A Canfrán-Duque, ... Cell reports 22 (8), 2133-2145, 2018 | 104 | 2018 |
Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes L Goedeke, RJ Perry, GI Shulman Annual review of pharmacology and toxicology 59, 65-87, 2019 | 72 | 2019 |